New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
Joint initiative part of LifeArc’s £100 million Translational Challenge to help address rare disease translational science.
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures
Dr Terri Cooper, Dr Sameer Mistry and Dr Rima Makarem join LifeArc's Board of Trustees as Non-Executive Directors.
EXPERTS-ALS to screen candidate drugs at scale and identify those that should be fast-tracked to larger clinical trials
£150,000 grant will fund a study of a biomarker test that could improve outcomes for patients with a rare sarcoma cancer.
LifeArc and PrecisionLife will work together to select and validate multiple novel targets and their accompanying patient stratification biomarkers.
Find out what this year's cohort of industrial placement students gained from the experience.
Focussing on innovative approaches to improve quality of life for people with cystic fibrosis (CF)